SPRY1 and neoplasm: Furthermore, inasmuch as tumor-induced T cell anergy inhibits the anti-tumor effector response, it is possible that blocking Spry1 during the effector phase of the anti-tumor response might further enhance the efficacy of tumor immunotherapy.